Intervene in the
sickle cell disease
(SCD) cascade1,2

Intervene in the sickle cell disease (SCD) cascade1,2

Oxbryta directly inhibits hemoglobin S (HbS) polymerization and subsequent red blood cell (RBC) sickling to reduce hemolysis and improve anemia

Watch how Oxbryta intervenes

Oxbryta improves anemia and reduces hemolysis1,2

  • Improves anemia as measured by greater than 1 g/dL hemoglobin (Hb) increase vs baseline (51% vs 7%) compared to placebo
  • Reduces hemolysis as measured by indirect bilirubin (-29% vs -3%) and percent reticulocyte count (-20% vs 5%) vs baseline compared to placebo. Mean Hb improvement in the Oxbryta group was 1.1 g/dL at 24 weeks
See the efficacy results
  • Improves anemia as measured by greater than 1 g/dL hemoglobin (Hb) increase vs baseline
    (51% vs 7%) compared to placebo
  • Reduces hemolysis as measured by indirect bilirubin (-29% vs -3%) and percent reticulocyte
    count (-20% vs 5%) vs baseline compared to placebo. Mean Hb improvement in the Oxbryta
    group was 1.1 g/dL at 24 weeks
See the efficacy results

Convenient oral dosing:
3 tablets, once a day,
with or without hydroxyurea1

View dosing schedule and adjustments

GBT Source Solutions helps Oxbryta patients
throughout their treatment journey

Enroll your Oxbryta patients in GBT Source Solutions for support while on therapy

Learn about access and support

Watch medical experts discuss the Oxbryta clinical data, safety profile, and appropriate patients they would consider for Oxbryta

Browse video resources

Participants were compensated for their time.

Get the latest information about Oxbryta delivered to your inbox